BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

U.S. Federal Bankruptcy Court Confirms Cobalis Corp. (CLSC.OB)'s Plan of Reorganization


4/12/2010 8:05:04 AM

IRVINE, CA--(Marketwire - 04/12/10) - Federal Bankruptcy Court Judge Theodor C. Albert, of the Central District of California issued his final ruling on April 7, 2010, handing Cobalis Corp (Pinksheets:CLSC - News) a resounding victory by confirming Cobalis Corp's plan of reorganization. Upon confirmation, Cobalis will officially emerge from bankruptcy, with requirements to pay its creditors over a 5-year period.

In deciding his ruling, Judge Albert heard and reviewed extensive testimony, documents and expert opinions from both Cobalis Corp and from YA Global (formerly known as Cornell Capital), which filed a competing plan that the Court did not confirm.

Judge Albert decided that Cobalis' plan for reorganization met all the criteria of The United States Bankruptcy Code, and afforded Cobalis' creditors, shareholders and investors a significantly higher level of protection than did YA Global's competing plan which would have eliminated all current shareholder equity.

Under the now-approved Cobalis plan of reorganization, all classes of creditors will be paid in full on their allowed claims with interest as determined by the Court, fully amortized over a five year term in monthly installments. Management believes it may well be able to meet these obligations in a shorter term, based on revenues generated. As Cobalis continues to dispute certain creditor claims, including those of YA Global, payments will be paid into an escrow account on the same schedule. Notably, under Cobalis' plan, existing shares in Cobalis are preserved.

Commenting on the litigation contesting the amount owed to YA Global, the Court stated: "Even though the Court has discounted the litigation threat on a temporary basis for voting purposes, if debtor prevails, it is conceivable that no amount would be owed YA Global and this could be determined well in advance of the payment schedule facing all others."

As the Court made clear at the confirmation hearing, "If debtor's plan is confirmable then it alone should receive the confirmation order as instructed by 11 U.S.C. Section1129(c) since it alone provides something for the shareholders and, as well, it is supported by a much wider margin of the unsecured creditors."

Cobalis CEO Chas Radovich said: "The Court's confirmation of Cobalis' plan of reorganization and our emergence from bankruptcy represents a true turning point for Cobalis, and endorses our unwavering commitment to protect our shareholders. We view the Court's confirmation of our plan as vindication of what we have believed from the beginning -- Cobalis has a viable and feasible plan to bring an amazing product in PreHistin® to market to help the hundreds of millions of allergy sufferers worldwide find a better alternative to after-the-fact antihistamines. As we move forward now out of bankruptcy, the Company intends to return to a fully-reporting status and fulfill our obligations to creditors under our plan of reorganization. We especially thank our shareholders, stakeholders and investors as well as our directors, management, advisors, legal team and creditors who have stood by us during this contentious period. We look forward to building a strong, profitable company well into the future."

ABOUT COBALIS CORP -- PREHISTIN®

Cobalis Corp. is an over the counter pharmaceutical and nutraceutical development company. Its flagship product, "PreHistin®, The World's FIRST Pre-Histamine"™, is a natural, safe and clinically proven formula designed to mitigate overproduction of IgE levels, to restore normal response to seasonal and year-round indoor and outdoor allergens and reduce the likelihood of onset of allergy symptoms resulting from histamine release. PreHistin® is available without prescription for both long-term and daily use.

For PreHistin® product information and ordering please visit at http://www.prehistin.com/ or call toll free 1-877-4POLLEN. For additional company information please visit their website at http://www.cobalis.com/.

CONTACT: Cobalis Corporation 2030 Main St., Suite 1300 Irvine, CA 92614 949-260-9007 Chas Radovich

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES